Floatz logo

(+)-VINCRISTINE

Precursor B-Cell Lymphoblastic Leukemia

Therapeutic Advances in Childhood Leukemia ConsortiumSmall moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

25 Active assets in the Precursor B-Cell Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Blinatumomab
Amgen
Phase 3BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2/3BB
Cyclophosphamide
Princess Maxima Center for Pediatric Oncology
Phase 2/3BB
Cytosin-Arabinosid
Princess Maxima Center for Pediatric Oncology
Phase 2B
METHOTREXATE
First Affiliated Hospital of Zhejiang University
Phase 2B

View all 28 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →